Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of kidney cancer
3.2.1.2 Rising awareness and early diagnosis initiatives
3.2.1.3 Technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Renal cell carcinoma (RCC)
5.3 Transitional cell cancer
5.4 Wilms tumor
5.5 Renal sarcoma
Chapter 6 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Targeted therapy
6.3 Immunotherapy
6.4 Chemotherapy
6.5 Other therapies
Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Angiogenesis inhibitors
7.3 Monoclonal antibodies
7.4 mTOR inhibitors
7.5 Cytokine immunotherapy (IL-2)
7.6 Other drug classes
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Intravenous
8.4 Subcutaneous
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacy
9.3 Brick and mortar
9.4 E-commerce
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Active Biotech AB
11.2 Amgen, Inc.
11.3 Astellas Pharma Inc.
11.4 AstraZeneca PLC
11.5 Bayer AG
11.6 Bristol-Myers Squibb Company
11.7 Eisai Co., Ltd.
11.8 Exelixis, Inc.
11.9 F. Hoffmann-La Roche Ltd.
11.10 Genentech, Inc.
11.11 GSK plc
11.12 Helsinn Healthcare SA
11.13 Johnson & Johnson Services, Inc.
11.14 Merck & Co., Inc.
11.15 Novartis AG
